Poseida Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $71,748 | $25,973 | $28,142 | $24,995 |
Gross Profit | 71,748 | 24,624 | 26,762 | 20,819 |
EBITDA | 23,892 | -27,763 | -20,641 | -21,644 |
EBIT | 22,573 | -29,112 | -22,021 | -23,082 |
Net Income | 20,235 | -31,371 | -24,274 | -23,990 |
Net Change In Cash | 71,748 | 25,973 | 28,142 | 24,995 |
Free Cash Flow | -10,239 | 37,431 | -15,265 | -29,053 |
Cash | 49,340 | 30,545 | 53,297 | 44,472 |
Basic Shares | 98,219 | 96,965 | 96,019 | 90,185 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $64,703 | $130,361 | $31 | $0 |
Gross Profit | -92,069 | 125,189 | -4,520 | -2,586 |
EBITDA | -109,038 | -54,774 | -117,064 | -145,483 |
EBIT | -114,652 | -59,946 | -121,616 | -148,069 |
Net Income | -123,430 | -64,002 | 4,403 | 2,452 |
Net Change In Cash | 64,703 | 130,361 | 31 | 0 |
Cost of Revenue | -124,947 | 122,359 | -3,818 | |
Free Cash Flow | -95,233 | -30,696 | -105,177 | -130,236 |
Cash | 44,472 | 81,378 | 206,325 | 83,966 |
Basic Shares | 90,185 | 71,953 | 62,235 | 35,996 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | $0.21 |
2024-06-30 | -$0.32 |
2024-03-31 | -$0.25 |
2023-12-31 | -$0.27 |
